A bidirectional relationship exists between atrial fibrillation (AF) and chronic renal disease. Patients with AF have a higher incidence of renal dysfunction, and the latter predisposes to incident AF. The coexistence of both conditions results in a higher risk for thromboembolic-related adverse events but a paradoxical increased hemorrhagic risk. Oral anticoagulants 
C hronic kidney disease (CKD) is defined by
Kidney Disease Improving Global Outcomes as a reduction in renal function with a reduction in glomerular filtration rate (GFR) <60 ml/min/1.73 m 2 for 3 months or longer or with the presence of albuminuria (1, 2) . The scheme of CKD stages 1 to 5 is conventionally classified on the basis of GFR, ranging from CKD stage 1, which has preserved renal function (GFR >90 ml/min) to CKD stage 5, which has the worst renal function (GFR <15 ml/min). CKD has potential for gradual progression to end-stage renal disease (ESRD), which requires dialysis to correct the accompanying fluid and electrolyte imbalance.
The increasing incidence and prevalence of CKD are also associated with a parallel rise in incident atrial fibrillation (AF) (3) (4) (5) (6) . The main reason for this epidemiological coupling is the improving longevity in
Western countries, resulting in a rapidly increasing elderly population, as well as a contemporary increase in the collective risk factors shared by both conditions, such as diabetes mellitus and hypertension.
Unsurprisingly, CKD and AF are not independent conditions, as several studies and national registries have highlighted the increased incidence of AF among those with worsening renal function (7) (8) (9) (10) (11) (12) (13) (14) .
Indeed, the incidence of AF development can be as high as 12.1/1,000 patient-years in ESRD compared with 5.0/1,000 patient-years in controls (15) . Likewise, a new diagnosis of AF not only heralds the progression of CKD but also hastens the development of ESRD (16) (17) (18) . AF also leads to the progression of CKD, even among those with relatively "normal" renal function, with no detectable proteinuria on dipstick test at baseline (19) . Thus, a bidirectional relationship exists between these 2 conditions.
AF per se can result in increased risk of ischemic stroke and systemic thromboembolism and independently increased risk of cardiovascular death. However, the concurrent presence of both AF and CKD further exacerbates the stroke and mortality risks, with a 66% increase in relative risk of death (20) (21) (22) (23) .
Hence, the presence of both of these conditions results in an increase in the propensity for thromboembolism-related adverse events (including stroke, systemic thromboembolism, myocardial infarction, and death) but a paradoxical increase in hemorrhagic risk.
Stroke/thromboembolism and bleeding risks can be assessed using clinical risk scores, such as the CHA 2 DS 2 -VASc (congestive heart failure, hyperten- (26, 27) . Patients with severe renal impairment (CrCl <25 to 30 ml/min) were excluded from the phase 3 randomized trials of NOACs, so limited trial data are available.
Initially, this review discusses the pathophysiological and clinical bases underlying the increased risk of thromboembolism and hemorrhage among AF patients with CKD. Second, we review the data for the use of oral anticoagulants for stroke prevention in AF across the spectrum of renal dysfunction.
SEARCH STRATEGY
A comprehensive search of published studies was performed using electronic bibliographic databases Lau et al.
S E P T E M B E R 2 7 , 2 0 1 6 : 1 4 5 2 -6 4 AF, CKD, and Thromboembolic Risk calcium-phosphate mineral metabolism, which has been related to renal dysfunction (52-54).
EPIDEMIOLOGICAL INSIGHTS. An increase in stroke risk with progressive severe CKD among AF patients is evident from several large observational studies ( Table 2 ).
The ATRIA (AnTicoagulation and Risk factors In
Atrial fibrillation) study (55) CKD patients undergoing chronic dialysis had a 
CLINICAL MANAGEMENT OF AF AND CKD
The approach to clinical management of AF patients with CKD has recently been comprehensively addressed by a position paper from the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society (87).
In general, the management of AF is patient-centered and symptom-directed when it comes to deciding on rate or rhythm control strategies (88, 89) ; however, One recent study in European countries reported that patients with mild to moderate CKD were more likely treated with a rhythm control approach, whereas patients with severe CKD were more likely treated with a rate control approach (90) . Also, AF ablation procedures were infrequently performed in patients with advanced CKD (90).
This approach seems justified, given the lack of proven long-term efficacy of ablation procedures in patients with CKD. In fact, one meta-analysis of observational studies in this clinical setting found CKD to be associated with a higher AF recurrence risk (91) . Similar data have been reported for AF patients undergoing chronic dialysis (92) . Indeed, worsening renal function during follow-up after catheter ablation seems to be associated with the highest risk of AF recurrence (93) . In patients with new-onset AF after myocardial infarction, there were no significant differences in short-and long-term mortality rates between rate and rhythm control strategies in patients with CKD (94).
ORAL ANTICOAGULATION IN CKD: USING VITAMIN K ANTAGONISTS
Although oral anticoagulation is the mainstay of treatment for the prevention of ischemic stroke and thromboembolism in patients with AF, less evidence exists for those with significant renal impairment, given that such patients were excluded from the randomized trials. Hence, the prescription of oral anticoagulants (essentially VKAs, e.g., warfarin) among those with significant renal impairment varies from as low as 2% in Germany to as high as 37% in Canada (58) . This heterogeneity in clinical practice reflects the uncertainty about the risks and benefits of anticoagulation use within this patient group. Tables 1 and 2 .
Lau et al. Tables 1 and 3 .
Lau et al. Illustrative figure shows the apixaban dose for ESRF on hemodialysis as per U.S. regulatory labelling notwithstanding the lack of clinical trial evidence for the dosing in patients with end stage renal impairment and some discordance with the current ACC/AHA/HRS practice guidelines. We provide a suggested algorithm, set according to current evidence and guidelines, for the decision-making process in prescribing oral anticoagulant therapy in patients with various degrees of renal function impairment.
Careful evaluation of clinical factors is needed and is pivotal at every step of the process to correctly identify the best option for every patient. *Only approved in the 12. Horio T, Iwashima Y, Kamide K, et al. Chronic kidney disease as an independent risk factor for
